PhRMA Slams FTC's Rationale For Targeting Drugmakers

Law360, New York (March 25, 2014, 8:53 PM EDT) -- The Pharmaceutical Research and Manufacturers of America on Monday blasted the Federal Trade Commission’s argument that the agency has authority to issue industry-specific requirements and urged a D.C. federal judge to vacate a rule requiring pharmaceutical companies to report more exclusive patent licenses for approval under federal merger law.

In its opposition to the FTC’s bid for summary judgment, PhRMA claimed the agency did not have the power under the Hart-Scott-Rodino Act to issue a rule requiring pharmaceutical companies to report more exclusive patent licenses for...
To view the full article, register now.